冠心宁片联合沙库巴曲缬沙坦治疗冠心病合并慢性心力衰竭的临床研究  

Clinical Study of Guanxinning Tablets Combined with Sakobactri Valsartan in the Treatment of Coronary Heart Disease Complicated with Chronic Heart Failure

作　　者：韩钺[1] 陈生[1] 王亚琼[1] 熊广[1] HAN Yue;CHEN Sheng;WANG Ya-qiong;XIONG Guang(Shenzhen Traditional Chinese Medicine Hospital,Guangdong Shenzhen 518033)

机构地区：[1]深圳市中医院,广东深圳518033

出　　处：《深圳中西医结合杂志》2022年第11期13-17,共5页Shenzhen Journal of Integrated Traditional Chinese and Western Medicine

基　　金：深圳市卫生和计划生育委员会“三名工程”项目(SZSM201812063)。

摘　　要：目的:通过随机对照试验,观察冠心宁片联合沙库巴曲缬沙坦治疗冠心病合并慢性心力衰竭(CHF)的临床疗效,为临床医疗实践提供科学依据。方法:选取深圳市中医院2019年2月至2021年10月期间收治的100例冠心病合并CHF患者,随机分为观察组和对照组,各50例。对照组患者在常规治疗的基础上合用沙库巴曲缬沙坦,观察组患者在对照组的基础上加上冠心宁片治疗,疗程为6个月。观察比较两组患者的临床疗效,CHF标志物:氨基末端脑钠肽前体(NT-proBNP)和脑钠肽(BNP);心功能指标:左心室射血分数(LVEF),左心室舒张末期内径(LVEDD)和左心室收缩末期内径(LVESD),6 min步行试验(6MWT);神经内分泌激素:血管紧张素Ⅱ(AngⅡ)、醛固酮(ALD)和肾素活性(PRA);血脂水平:三酰甘油(TG),总胆固醇(TC),高密度脂蛋白胆固醇(HDL-C),低密度脂蛋白胆固醇(LDL-C);记录患者治疗过程中产生的不良反应。结果:观察组患者治疗总有效率为94.0%,高于对照组的78.0%,差异具有统计学意义(P<0.05),治疗后两组患者的血清NT-proBNP、BNP较治疗前降低,且治疗后观察组患者血清NT-proBNP、BNP均低于对照组,差异具有统计学意义(P<0.05)。治疗后两组患者LVEF较治疗前提高,LVEDD、LVESD较治疗前降低,且治疗后观察组患者LVEF高于对照组,LVEDD、LVESD均低于对照组,差异具有统计学意义(P<0.05)。治疗后两组患者6MWT均较治疗前提高,且治疗后观察组患者6MWT长于对照组,差异具有统计学意义(P<0.05),治疗后两组患者AngⅡ、ALD、PRA均较治疗前降低,且治疗后观察组患者的AngⅡ、ALD、PRA均低于对照组,差异具有统计学意义(P<0.05)。治疗后两组患者TG、TC、LDL-C均较治疗前降低,HDL-C较治疗前升高,且治疗后观察组患者TG、TC、LDL-C均低于对照组,HDL-C高于对照组,差异具有统计学意义(P<0.05)。两组患者的不良反应发生率比较,差异无统计学意义(P>0.05)。结论:冠心宁�Objective To observe the clinical efficacy of Guanxinning tablets combined with sakobactri valsartan in the treatment of coronary heart disease complicated with chronic heart failure(CHF),and to provide scientific basis for clinical medical practice.Methods A total of 100 patients with coronary heart disease complicated with CHF admitted to Shenzhen Traditional Chinese Medicine Hospital from February 2019 to October 2021 were randomly divided into an observation group and a control group,with 50 cases in each group.The control group was treated with sakobactri valsartan on the basis of conventional treatment,and the observation group was treated with guanxining tablets on the basis of the control group,for a course of 6 months.Clinical efficacy of the two groups were observed and compared.CHF markers:N terminal pro B type natriuretic peptide(NT-proBNP)and brain natriuretic peptide(BNP);cardiac function indicators:left ventricular ejection fraction(LVEF),left ventricular end diastolic diameter(LVEDD)and left ventricular end systolic diameter(LVESD),6 min walking test(6MWT);neuroendocrine hormone:angiotensinⅡ(AngⅡ),aldosterone(ALD)and plasma renin activity(PRA);blood lipid levels:triglyceride(TG),total cholesterol(TC),high density lipoprotein cholesterol(HDL-C),low density lipoprotein cholesterol(LDL-C);adverse reactions during treatment were recorded.Results The total effective rate of the observation group was 94.0%,higher than 78.0% of the control group,the difference was statistically significant(P<0.05).After treatment,the serum NT-proBNP and BNP of the two groups of patients were lower than those before treatment,the serum NT-proBNP and BNP of the observation group were lower than those of the control group,the differences were statistically significant(P<0.05).After treatment,LVEF in the two groups was increased,LVEDD and LVESD were decreased,and LVEF in the observation group was higher than that of the control group,while LVEDD and LVESD were lower than those of the control group,the differences were st

关 键 词：冠心病 慢性心力衰竭 冠心宁片 沙库巴曲缬沙坦 

分 类 号：R541[医药卫生—心血管疾病]